ViiV Healthcare premieres early data showing antiviral activity against integrase resistance from its investigational, third-generation integrase inhibitor
Issued: London, UK
For media and investors only
Download
(PDF, 196.9KB)
Data, along with results from a phase I study, are the first public presentation of VH4524184, which is part of the company’s long-term strategy to deliver ultra long-acting...
Zur Pressemeldung auf www.gsk.com
